2022
The Potential of N-acetyl Cysteine in Behavioral Addictions and Related Compulsive and Impulsive Behaviors and Disorders: a Scoping Review
Greenberg N, Farhadi F, Kazer B, Potenza M, Angarita G. The Potential of N-acetyl Cysteine in Behavioral Addictions and Related Compulsive and Impulsive Behaviors and Disorders: a Scoping Review. Current Addiction Reports 2022, 9: 660-670. PMID: 38362235, PMCID: PMC10868722, DOI: 10.1007/s40429-022-00446-3.Peer-Reviewed Original ResearchN-acetylcysteineSelf-injurious behaviorEffectiveness of NACEfficacy of NACSmall open-label trialsUse of NACCompulsive sexual behaviorOpen-label trialRepetitive self-injurious behaviorSexual behaviorCompulsive behaviorsGambling disorderGlutamate dysregulationBehavioral addictionsCase reportClinical trialsPreclinical studiesGlutamate homeostasisAcetyl cysteineDisordersMore studiesScoping ReviewCompulsive featuresAddictionImpulsive behavior
1999
Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders
Potenza M, Holmes J, Kanes S, McDougle C. Olanzapine Treatment of Children, Adolescents, and Adults with Pervasive Developmental Disorders. Journal Of Clinical Psychopharmacology 1999, 19: 37-44.. PMID: 9934941, DOI: 10.1097/00004714-199902000-00008.Peer-Reviewed Original ResearchConceptsPervasive developmental disorderClinical Global Impression ScaleWeight gainTolerability of olanzapineLiver function abnormalitiesExtrapyramidal side effectsGlobal Impression ScaleGlobal improvement itemTreatment of childrenSignificant adverse effectsDevelopmental disordersSelf-injurious behaviorClinical respondersOlanzapine treatmentFunction abnormalitiesDaily doseOverall symptomsPatient populationImpression ScalePrincipal diagnosisMotor restlessnessProspective fashionWeek 4Related symptomsSide effects